Beauty is in the eye of the beholder. I've seen no evidence to show why the upcoming bryostatin results aren't positive and I've seen no science that explains why 273 might not fail like these examples did...and there are more than this. Of course there is no scientific evidence in controlled trials to base decisions on so that will be the chance one takes moving forward on avxl. Not the case with NTRP of course.
Market Data 
Markets 
AI
